Pharm
Clarithromycin
search
Clarithromycin
, Biaxin
See also
Macrolide
Erythromycin
Indications
Conditions
Community Acquired Pneumonia
Limit to suspected
Mycoplasma pneumonia
or
Legionella pneumonia
Macrolide
resistant pneumococcus is common
Consider
Doxycycline
as alternative
Streptococcal Pharyngitis
Macrolide
s are only indicated in significant allergy to beta-lactams
Non-tuberculous
Mycobacteria
l infections
Helicobacter
infections
Activity
Macrolide
resistance is increasing
Resistance to one
Macrolide
is resistance to all
Spectrum includes organisms covered by
Erythromycin
Streptococcus Pneumoniae
(Pneumococcus)
Staphylococcus aureus
Toxoplasmosis
gondii
Mycobacterium leprae
Mycobacterium Avium Complex
Borrelia Burgdorferi
Medications
Tablets: 250 and 500 mg
Suspension: 125 and 250 mg/5 ml
Dosing
See
Pertussis
May take with or without food
Gene
ral
Adult: 250 to 500 mg orally twice daily
Child: 7.5 mg/kg orally twice daily
Group A Streptococcal Pharyngitis
(second line agent in beta lactam allergy)
Adult: Take 250 mg orally twice daily for 10 days
Child: 7.5 mg orally twice daily for 10 days
Acute Exacerbation of Chronic Bronchitis
Adult: Take 250 mg orally twice daily for 7 to 14 days
Mycobacterium Avium Complex
Disease (e.g.
AIDS
)
Adult: 500 mg orally twice daily
Active disease is treated with at least 2 drugs
Renal Dosing
eGFR 30 to 60 ml/min: Decrease dose by 50%
eGFR <30 ml/min: Decrease dose by 75%
Pharmacokinetics
Half Life: 5 hours
Adverse Effects
See
Macrolide
Dysgeusia
or
Distorted Taste
(20%)
Calcium Channel Blocker
Drug Interaction
(see below)
Myasthenia Gravis
(risk of exacerbation)
QT Prolongation
Appears to be a class effect of
Macrolide
s, but seen more with
Azithromycin
Higher risk with known
QTc Prolongation
,
Hypokalemia
,
Hypomagnesemia
, Class IA or III
Antiarrhythmic
s
Increased cardiovascular deaths
Observation in some studies as of 2018, but needs confirmation
Inghammer (2017) Am J Epidemiol +PMID:29155931 [PubMed]
Svanström (2014) BMJ 349:g4930 +PMID:25139799 [PubMed]
Safety
Considered safe in
Lactation
Pregnancy Category C
Clarithromycin is considered a potential
Teratogen
(
Cleft Lip
association)
Macrolide
s in general may increase heart defects with first trimester exposure of 5-7 days
Fan (2020) BMJ 368: m331 +PMID:32075790 [PubMed]
Drug Interactions
Clarithromycin is a strong
CYP3A4
inhibitor
Includes
Calcium Channel Blocker
s as below
Numerous interactions including
Carbamazepine
,
Quetiapine
,
Simvastatin
Toxicity risks with
Ergotamine
s and
Colchicine
Warfarin
May increase INR
Calcium Channel Blocker
s
Clarithromycin increases
Calcium Channel Blocker
levels via
CYP3A4
inhibition
Highest risk with
Dihydropyridine Calcium Channel Blocker
s (
Nifedipine
,
Felodipine
)
Highest risk in age over 65 years old
Provokes
Hypotension
and
Bradycardia
Risk of
Acute Kidney Injury
(often requiring hospitalization)
Number needed to harm: 1 in 465 for over age 65 years
References
Gandhi (2013) JAMA 310(23):2544-53 [PubMed]
Resources
Clarithromycin Tablet (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b98b02bb-2609-49a0-b29f-e5911aa0cbc1
Type your search phrase here